Market research
23J.F ProMIS Neurosciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 97M
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.22
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA74346M5054
- Market cap
- 97M
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.22
About
About ProMIS Neurosciences, Inc
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 23J.F discussion.
5 years, 5 months ago
ProMIS Neurosciences, Inc is currently in a long term uptrend where the price is trading 47.1% above its 200 day moving average.
From a valuation standpoint, the stock is 1317.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 18617.6.
ProMIS Neurosciences, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 7.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 33.1% to $-940K since the same quarter in the previous year.
Based on the above factors, ProMIS Neurosciences, Inc gets an overall score of 2/5.